Genentech Rituxan Promotions Under Investigation By DoJ
Executive Summary
Genentech is responding to a subpoena regarding its promotions of the oncologic agent Rituxan
You may also be interested in...
Genentech Plans Avastin/Tarceva Combo Filing; Avastin Warning Hurts Growth
Genentech and OSI Pharmaceuticals will be meeting with FDA early in 2005 to discuss filing plans for Tarceva (erlotinib) in pancreatic cancer
Genentech Plans Avastin/Tarceva Combo Filing; Avastin Warning Hurts Growth
Genentech and OSI Pharmaceuticals will be meeting with FDA early in 2005 to discuss filing plans for Tarceva (erlotinib) in pancreatic cancer
Genentech Rituxan Sales Level Off; Manufacturing Issues Resolved
Sales of Genentech's Rituxan appear to be leveling off as the product approaches full penetration in its largest markets